NCT01835665View on ClinicalTrials.gov

Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Progranulin Mutation Carriers
Interventions
DRUG

Nimodipine

Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication

Trial Locations (1)

94158

UCSF Memory and Aging Center, San Francisco

All Listed Sponsors
collaborator

The Bluefield Project to Cure Frontotemporal Dementia

OTHER

lead

University of California, San Francisco

OTHER

NCT01835665 - Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations | Biotech Hunter | Biotech Hunter